| All Releases |
 |
Dyax Corp. Reaffirms Commitment to Supporting Patients with Hereditary Angioedema on Inaugural HAE Day
May 16, 2012
|
219.9 KB |
|
| |
$25,000 donated to the United States Hereditary Angioedema
Association from Multiple Fundraising Initiatives
BURLINGTON, Mass.--(BUSINESS WIRE)--
As awareness activities take place today across the globe in recognition
of Hereditary Angioedema (HAE) Day —— Dyax
Corp. (NA...
|
|
Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Tracker™, a Free iPhone Application for HAE Patients
May 11, 2012
|
20.7 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax
Corp. (NASDAQ: DYAX) today announced the launch of a free smartphone
application for the iPhone — HAE Attack Tracker™. This
application allows HAE patients to keep detailed records of their
disease related information, including emergency and physicia...
|
|
Dyax Corp. to Participate in the Deutsche Bank 37th Annual Healthcare Conference
May 1, 2012
|
18.7 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax
Corp. (NASDAQ: DYAX) announced today that executive management will
participate in the Deutsche Bank 37th Annual Healthcare
Conference, being held May 7-9, 2012 at the InterContinental Hotel in
Boston. Gustav Christensen, President and Chief Executive Officer of
...
|
|
Dyax Corp. Announces First Quarter 2012 Financial Results
Apr 24, 2012
|
33.1 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the
first quarter ended March 31, 2012. Dyax will host a webcast and
conference call at 5:00 p.m. (ET) today to review financial results and
provide updates regarding its key value drivers — the KALBITOR...
|
|
Dyax Corp. to Host First Quarter 2012 Earnings Call and Webcast
Apr 18, 2012
|
20.1 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ:DYAX)
will host a webcast and conference call, including an open question and
answer session, Tuesday, April 24, 2012. During the call, management
will discuss the Company's financial results for the first quarter
ending March 31, 2012 and progress ...
|
|
Dyax and Eclipse Therapeutics Announce Oncology Antibody License Agreement
Apr 17, 2012
|
24.7 KB |
|
| |
BURLINGTON, Mass. & SAN DIEGO, Calif.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ:DYAX) and Eclipse Therapeutics, Inc., a privately
held oncology company, announced today that Dyax has granted Eclipse an
exclusive worldwide license for the development and commercialization of
preclinical fully-human antibodies discover...
|
|
Dyax Launches Hereditary Angioedema Genetic Counseling Program to Educate Patients and Family Members about Disease and Inheritance
Apr 11, 2012
|
22.4 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax
Corp. (NASDAQ: DYAX) the manufacturer of KALBITOR®
(ecallantide) for the treatment of acute attacks of hereditary
angioedema (HAE) in patients 16 years of age and older, has announced
the launch of its HAE genetic counseling program. The program, which is
...
|
|
GE Healthcare and Dyax Announce Licensing Agreement for c-Met Imaging Peptides for Use in Colorectal, Lung and Liver Cancer Research
Mar 31, 2012
|
22.6 KB |
|
| |
CHALFONT ST GILES, England & BURLINGTON, Mass.--(BUSINESS WIRE)--
GE Healthcare, a unit of GE (NYSE:GE), and Dyax Corp. (NASDAQ:DYAX)
today announced a licensing agreement for the development and
commercialization of peptides binding to c-Met, which provides upfront,
milestone, and royalty payments to Dyax. Resea...
|
|
Dyax Corp. to Participate in the Needham & Company 11th Annual Healthcare Conference
Mar 27, 2012
|
18.8 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax
Corp. (NASDAQ: DYAX) announced today that executive management will
participate in the Needham and Company 11th Annual Healthcare
Conference, being held April 3-4, 2012 at the New York Palace Hotel in
New York City. Gustav Christensen, President and Chief Executi...
|
|
Dyax Kicks Off Fundraising Activities in Honor of First Ever HAE Day — A Global Event to Raise Awareness of Hereditary Angioedema
Mar 20, 2012
|
22.8 KB |
|
| |
Company raises $17,700 for the United States Hereditary Angioedema
Association at the American Academy of Allergy, Asthma and Immunology
Annual Meeting
BURLINGTON, Mass.--(BUSINESS WIRE)--
In honor of the first ever HAE Day upcoming on May 16, 2012, Dyax Corp.
(NASDAQ: DYAX), the ma...
|
|
KALBITOR® (ecallantide) Data Presented at American Academy of Allergy, Asthma and Immunology Annual Meeting
Mar 6, 2012
|
29.5 KB |
|
| |
-Low Rebound and Relapse Rates Observed in Patients Treated with
KALBITOR-
-KALBITOR Study Data Demonstrate Clinically Meaningful Efficacy in
Treatment of Acute Laryngeal Attacks of Hereditary Angioedema-
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX)...
|
|
Dyax Announces Appointment of Dr. Burt Adelman as Chief Medical Officer
Feb 29, 2012
|
20.4 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX) announced today the appointment of Burt
Adelman, M.D. as Chief Medical Officer. Dr. Adelman will lead the
development and regulatory strategy for the Company's
non-histamine-mediated angioedema franchise.
Dr. Adelman has exper...
|
|
Dyax Corp. to Participate in Upcoming 2012 Healthcare Conferences
Feb 24, 2012
|
18.5 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax
Corp. (NASDAQ: DYAX) announced today that executive management will
participate in two upcoming conferences.
Gustav Christensen, President and CEO of Dyax, will present at the Citi
2012 Global Healthcare Conference on Monday, February 27 at 4:30 P...
|
|
Dyax Corp. Announces Fourth Quarter and Full Year 2011 Financial Results
Feb 22, 2012
|
37.6 KB |
|
| |
Company Announces Corporate Initiatives to Focus On and Grow the
Angioedema Franchise and LFRP
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the
fourth quarter and year ended December 31, 2011. Dyax will host a
webcast and confe...
|
|
Dyax Corp. to Host Fourth Quarter and Year End 2011 Earnings Call and Webcast
Feb 15, 2012
|
18.8 KB |
|
| |
BURLINGTON, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ:DYAX)
will host a webcast and conference call, including an open question and
answer session, Wednesday, February 22, 2012. During the call,
management will discuss the Company's financial results for the fourth
quarter and the year ended December 3...
|
|
Dyax Corp. Enters into New Loan Agreement with Cowen Healthcare Royalty Partners
Jan 4, 2012
|
21.8 KB |
|
| |
$80 Million Commitment Provides $20 Million in Cash and
Refinancing of Existing Loan at Reduced Interest Rate
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX) announced today that it has entered into a
loan agreement with an affiliate of Cowen Healthcare Royalty Partners
...
|
|
Dyax Corp. Provides Update on International Regulatory Status of KALBITOR® (ecallantide)
Nov 14, 2011
|
19.3 KB |
|
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX) announced today an update on KALBITOR's
international regulatory status.
Dyax and Defiante Farmaceutica S.A. (Defiante), an affiliate of the
pharmaceutical group Sigma-Tau, have reached a joint decision to
withdraw the Marketin...
|
|
KALBITOR® (ecallantide) Data in HAE Presented at the American College of Allergy, Asthma and Immunology Annual Meeting
Nov 7, 2011
|
27.8 KB |
|
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX)
announced today that two oral and two poster presentations featuring
KALBITOR® (ecallantide) data in hereditary angioedema (HAE)
were presented at the American College of Allergy, Asthma and Immunology
(ACAAI) Annual Meeting held November...
|
|
Dyax Corp. Appoints Ron Cohen, M.D. and Paolo Pucci to Board of Directors
Nov 1, 2011
|
20.0 KB |
|
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for
unmet medical needs, announced today the appointment of Ron Cohen, M.D.
and Paolo Pucci to its Board of Directors. In addition to their
appointment as Directors, Dr. Cohen will serve on the Compensation
...
|
|
Dyax Corp. Announces Third Quarter 2011 Financial Results
Oct 27, 2011
|
35.4 KB |
|
| |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the
third quarter ended September 30, 2011. Dyax will host a webcast and
conference call at 5 p.m. (ET) today to review financial results. Senior
management will also share updates regarding the Company's three maj...
|
|
|
0.01 (0.63)%
Briefcase
Email Alerts
IR Contacts
RSS Feeds
Mobile Investor